Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc (TMO) Stock Analysis

$673.820

-2.695 (-0.40%)At close

Loading chart…
High
677.280
Open
672.690
VWAP
671.20
Volume
2.04M
Mkt Cap
210.24B
Low
662.503
Amount
1.37B
EV/EBITDA, TTM
23.29

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.

AI analysis of Thermo Fisher Scientific Inc (TMO)

Buy

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.

Analyst Ratings (15)

-2.22% Downside
Buy
14 Buy
1 Hold
0 Sell
Current: 673.82
Low
580.00
Average
658.89
High
750.00

Morgan Stanley

2026-10-12

Price Target

$730

Overweight

BofA

2026-10-09

Price Target

$745

Buy

Barclays

2026-10-07

Price Target

$750

Overweight

Deutsche Bank

2026-09-25

Price Target

$720

Buy

UBS

2026-09-09

Price Target

$730

Buy

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO) is 24.15, compared to its 5-year average forward P/E of 23.79.

Forward P/E

Fair
5Y Average P/E
23.79
Current P/E
24.15
Overvalued
26.59
Undervalued
20.99

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
20.76
Current EV/EBITDA
23.29
Overvalued
22.70
Undervalued
18.82

Forward P/S

Fair
5Y Average P/S
4.71
Current P/S
5.09
Overvalued
5.35
Undervalued
4.06

Alphio AI Price Scenarios for TMO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TMO

$539.08

Scenario price

B

Base

Base · 50%TMO

$476.92

Scenario price

B

Bear

Bear · 25%TMO

$435.11

Scenario price

Whales holding TMO

C

Corient Private Wealth LP

+ HoldingTMO

+49.46%

3M Return

B

Braidwell LP

+ HoldingTMO

+24.47%

3M Return

W

W1M Investment Management Limited

+ HoldingTMOGEV

+16.55%

3M Return

H

Howard Capital Management, Inc.

+ HoldingTMO

+13.89%

3M Return

R

Route One Investment Company, L.P.

+ HoldingTMO

+10.01%

3M Return

C

Campbell & Company, LP

+ HoldingTMO

+9.56%

3M Return

Events Timeline

2026-10-21 (ET)

16:30:00

Nasdaq Rises on SpaceX Earnings Report

12:30:00

SpaceX Reports First Profit, Tesla Merger Proposal Gains Attention

09:00:00

Company Raises FY26 Revenue Outlook to $47.7B-$48.2B

09:00:00

Stock Futures Rise as Brent Crude Surpasses $110

06:30:00

Company Reports Q3 Revenue of $12.4B, Beating Expectations

News

TMO FAQ — answered by Alphio AI

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.

15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.

Community

More ↗
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading